Latest News and Press Releases

This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.

WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.

Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.

Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.

Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.

Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.

Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.